Jacquelyn Sumer
Compliance Officer en CULLINAN THERAPEUTICS, INC. .
Fortuna: 2 M $ al 31/03/2024
Perfil
Jacquelyn Sumer is currently working as the Secretary, Chief Legal & Compliance Officer at Cullinan Oncology, Inc. She previously worked as the Executive Director & Senior Corporate Counsel at Celgene Corp.
from 2017 to 2018.
She also worked as the Vice President & Assistant General Counsel at Bristol Myers Squibb Co. and as the Chief Legal & Compliance Officer at Genocea Biosciences, Inc. Ms. Sumer completed her undergraduate degree at Bucknell University and her graduate degree at Duke University School of Law.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 22/02/2024 | 94 133 ( 0.22% ) | 2 M $ | 31/03/2024 |
Cargos activos de Jacquelyn Sumer
| Empresas | Cargo | Inicio |
|---|---|---|
| CULLINAN THERAPEUTICS, INC. | Compliance Officer | 15/08/2022 |
Antiguos cargos conocidos de Jacquelyn Sumer.
| Empresas | Cargo | Fin |
|---|---|---|
| CELGENE | Director/Board Member | 01/07/2018 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
| GENOCEA BIOSCIENCES, INC. | Compliance Officer | - |
Formación de Jacquelyn Sumer.
| Bucknell University | Undergraduate Degree |
| Duke University School of Law | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| CULLINAN THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
- Bolsa de valores
- Insiders
- Jacquelyn Sumer
